Moderna has secured up to 60 million dollars from CEPI to develop a modified mRNA vaccine for Ebola Bundibugyo. This comes amid an outbreak in Congo with 282 confirmed cases and 42 deaths, plus cases in Uganda.

Moderna is moving forward with plans to create a modified mRNA vaccine aimed at the Ebola Bundibugyo strain. The company received funding of up to 60 million dollars from the Coalition for Epidemic Preparedness Innovations. This support aims to speed up the development process during current health concerns.

The outbreak in eastern Democratic Republic of Congo has led to 282 confirmed cases and 42 deaths so far. There are also around 1,100 suspected cases in the region. In addition, Uganda has reported nine confirmed cases with one death. Health experts continue to monitor the situation closely.

This effort highlights ongoing work in vaccine technology to address infectious diseases. The focus remains on safety and effectiveness as development progresses.

Original Author: Jessica Rose | Source: Brownstone Institute